{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:55:03Z","timestamp":1791665703056,"version":"4.3.4"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurosurgery Clinics of North America"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.nec.2023.02.012","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T17:36:03Z","timestamp":1680716163000},"page":"447-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Novel Systemic Approaches for the Management of Meningiomas"],"prefix":"10.1016","volume":"34","author":[{"given":"Nazanin","family":"Ijad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert E.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Wakimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tareq A.","family":"Juratli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla K.","family":"Brastianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nec.2023.02.012_bib1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/jnnp-2019-322257","article-title":"Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis","volume":"91","author":"Mirian","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.nec.2023.02.012_bib4","doi-asserted-by":"crossref","first-page":"851758","DOI":"10.3389\/fonc.2022.851758","article-title":"Identification and management of aggressive meningiomas","volume":"12","author":"Patel","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib5","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.wneu.2011.05.015","article-title":"Long-term 25-year follow-up of surgically treated parasagittal meningiomas","volume":"76","author":"Pettersson-Segerlind","year":"2011","journal-title":"World Neurosurg"},{"key":"10.1016\/j.nec.2023.02.012_bib6","doi-asserted-by":"crossref","first-page":"109228","DOI":"10.18632\/oncotarget.22650","article-title":"Intratumoral heterogeneity and TERT promoter mutations in progressive\/higher-grade meningiomas","volume":"8","author":"Juratli","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.nec.2023.02.012_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/neuros\/nyy154","article-title":"TERT Alterations in progressive treatment-resistant meningiomas","volume":"65","author":"Juratli","year":"2018","journal-title":"Neurosurgery"},{"key":"10.1016\/j.nec.2023.02.012_bib8","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00401-018-1899-7","article-title":"DMD genomic deletions characterize a subset of progressive\/higher-grade meningiomas with poor outcome","volume":"136","author":"Juratli","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.nec.2023.02.012_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s40478-020-01040-2","article-title":"Distinct genomic subclasses of high-grade\/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic","volume":"8","author":"Williams","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.nec.2023.02.012_bib10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bpa.12110","article-title":"High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression","volume":"24","author":"Goutagny","year":"2014","journal-title":"Brain Pathol"},{"key":"10.1016\/j.nec.2023.02.012_bib11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11060-019-03333-6","article-title":"Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma","volume":"145","author":"Guyot","year":"2019","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib12","first-page":"1022","article-title":"Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas","volume":"54","author":"Lekanne Deprez","year":"1994","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nec.2023.02.012_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2","volume":"363","author":"Rouleau","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.nec.2023.02.012_bib14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0294-180","article-title":"Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas","volume":"6","author":"Ruttledge","year":"1994","journal-title":"Nat Genet"},{"key":"10.1016\/j.nec.2023.02.012_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.nec.2023.02.012_bib16","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.nec.2023.02.012_bib17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nov316","article-title":"Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma","volume":"18","author":"Abedalthagafi","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-013-1187-5","article-title":"AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry","volume":"126","author":"Sahm","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.nec.2023.02.012_bib19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature05933","article-title":"A\u00a0transforming mutation in the pleckstrin homology domain of AKT1 in cancer","volume":"448","author":"Carpten","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.nec.2023.02.012_bib20","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2014-03-559963","article-title":"The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma","volume":"124","author":"Spencer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.nec.2023.02.012_bib21","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.73.0143","article-title":"AKT inhibition in solid tumors With AKT1 mutations","volume":"35","author":"Hyman","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djw320","article-title":"Durable control of metastatic AKT1-mutant WHO grade 1 meningothelial meningioma by the AKT inhibitor, AZD5363","volume":"109","author":"Weller","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.nec.2023.02.012_bib23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0092-8674(00)81268-4","article-title":"Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome","volume":"85","author":"Hahn","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.nec.2023.02.012_bib24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00401-022-02474-9","article-title":"Two predominant molecular subtypes of spinal meningioma: thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord","volume":"144","author":"Hua","year":"2022","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.nec.2023.02.012_bib25","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1038\/s41467-020-18582-7","article-title":"Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma","volume":"11","author":"Magill","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.nec.2023.02.012_bib26","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","article-title":"Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities","volume":"54","author":"Choudhury","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.nec.2023.02.012_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40478-020-01113-2","article-title":"Sporadic multiple meningiomas harbor distinct driver mutations","volume":"9","author":"Juratli","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.nec.2023.02.012_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","article-title":"A\u00a0clinically applicable integrative molecular classification of meningiomas","volume":"597","author":"Nassiri","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.nec.2023.02.012_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13073-022-01051-9","article-title":"Single-cell profiling of human dura and meningioma reveals cellular meningeal landscape and insights into meningioma immune response","volume":"14","author":"Wang","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.nec.2023.02.012_bib30","doi-asserted-by":"crossref","first-page":"e12970","DOI":"10.1111\/bpa.12970","article-title":"Prognostic impact of genetic alterations and methylation classes in meningioma","volume":"32","author":"Berghoff","year":"2022","journal-title":"Brain Pathol"},{"key":"10.1016\/j.nec.2023.02.012_bib31","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.21.00784","article-title":"Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated","volume":"39","author":"Maas","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib32","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejca.2017.07.026","article-title":"Hypermutated tumours in the era of immunotherapy: the paradigm of personalised medicine","volume":"84","author":"Nebot-Bral","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nec.2023.02.012_bib33","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.nec.2023.02.012_bib34","doi-asserted-by":"crossref","first-page":"38421","DOI":"10.18632\/oncotarget.5376","article-title":"Distinguishing grade I meningioma from higher grade meningiomas without biopsy","volume":"6","author":"Varlotto","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.nec.2023.02.012_bib35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/0394632017730241","article-title":"Innate immunity may play a role in growth and relapse of chordoid meningioma","volume":"30","author":"Presta","year":"2017","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.nec.2023.02.012_bib36","first-page":"vdz018","article-title":"Tumor-associated macrophage infiltration in meningioma","volume":"1","author":"Proctor","year":"2019","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.nec.2023.02.012_bib37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1471-2407-10-112","article-title":"The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time","volume":"10","author":"Ma","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.nec.2023.02.012_bib38","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.3171\/2018.1.FOCUS17754","article-title":"Medical management of meningioma in the era of precision medicine","volume":"44","author":"Gupta","year":"2018","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.nec.2023.02.012_bib39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/biomedicines6030086","article-title":"Emerging medical treatments for meningioma in the molecular era","volume":"6","author":"Nigim","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.nec.2023.02.012_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/neuros\/nyab001","article-title":"Meningioma: a pathology perspective","volume":"89","author":"Toland","year":"2021","journal-title":"Neurosurgery"},{"key":"10.1016\/j.nec.2023.02.012_bib41","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial","volume":"26","author":"Graillon","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nec.2023.02.012_bib42","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1200\/JCO.2020.38.15_suppl.2502","article-title":"Alliance A071401: phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations","volume":"38","author":"Brastianos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib43","first-page":"vdac123","article-title":"A\u00a0multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma","volume":"4","author":"Kumthekar","year":"2022","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.nec.2023.02.012_bib44","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib45","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-011-0687-1","article-title":"Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma","volume":"106","author":"Reardon","year":"2012","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-014-1358-9","article-title":"A\u00a0phase II trial of PTK787\/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas","volume":"117","author":"Raizer","year":"2014","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib47","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","article-title":"A\u00a0phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma","volume":"129","author":"Shih","year":"2016","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib48","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1215\/15228517-2009-010","article-title":"Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)","volume":"11","author":"Wen","year":"2009","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/neuonc\/nop017","article-title":"A\u00a0phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas","volume":"12","author":"Raizer","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib50","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/lio2.643","article-title":"Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas","volume":"6","author":"Welling","year":"2021","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"10.1016\/j.nec.2023.02.012_bib51","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2021.39.15_suppl.2024","article-title":"Multi-center, single arm phase II study of the dual mTORC1\/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas","volume":"39","author":"Plotkin","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib52","doi-asserted-by":"crossref","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.nec.2023.02.012_bib53","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.21.02371","article-title":"Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations","volume":"41","author":"Brastianos","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib54","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/annonc\/mdq634","article-title":"Bevacizumab-induced regression of anaplastic meningioma","volume":"21","author":"Puchner","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib55","first-page":"1301","article-title":"Everolimus effectively blocks pulmonary metastases from meningioma","volume":"17","author":"Bertolini","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib56","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1006416003964","article-title":"VEGF in brain tumors","volume":"50","author":"Machein","year":"2000","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2990.1997.tb01193.x","article-title":"Cell-adhesion molecules in human meningiomas: correlation with clinical and morphological data","volume":"23","author":"Figarella-Branger","year":"1997","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.nec.2023.02.012_bib58","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11523-019-00654-4","article-title":"A\u00a0monoclonal antibody against beta1 integrin inhibits proliferation and increases survival in an orthotopic model of high-grade meningioma","volume":"14","author":"Nigim","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib59","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1158\/0008-5472.CAN-13-0011","article-title":"beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma","volume":"73","author":"Carbonell","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.nec.2023.02.012_bib60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/pharmaceutics13010040","article-title":"Convection-enhanced delivery of a first-in-class anti-beta1 integrin antibody for the treatment of high-grade glioma utilizing real-time imaging","volume":"13","author":"Nwagwu","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nec.2023.02.012_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.nec.2023.02.012_bib62","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41467-022-29052-7","article-title":"Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas","volume":"13","author":"Brastianos","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.nec.2023.02.012_bib63","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/neuonc\/noab118","article-title":"Activity of PD-1 blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results","volume":"24","author":"Bi","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib64","article-title":"Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade","volume":"2018","author":"Dunn","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib65","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1200\/JCO.2022.40.16_suppl.2068","article-title":"The interim result of a phase I\/II study of nivolumab with or without ipilimumab in combination with multi-fraction stereotactic radiosurgery for recurrent, high-grade, radiation-relapsed meningioma","volume":"40","author":"Huang","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.nec.2023.02.012_bib66","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130688","article-title":"Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK","volume":"4","author":"Giles","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.nec.2023.02.012_bib67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.nec.2023.02.012_bib68","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T Cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.nec.2023.02.012_bib69","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.nec.2023.02.012_bib70","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.wneu.2019.10.044","article-title":"Expression and clinical significance of immune checkpoint regulator B7-H3 (CD276) in human meningioma","volume":"135","author":"Deng","year":"2020","journal-title":"World Neurosurg"},{"key":"10.1016\/j.nec.2023.02.012_bib71","doi-asserted-by":"crossref","first-page":"e1137","DOI":"10.1002\/cti2.1137","article-title":"Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma","volume":"9","author":"Tang","year":"2020","journal-title":"Clin Transl Immunology"}],"container-title":["Neurosurgery Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042368023000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042368023000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:04:42Z","timestamp":1760904282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1042368023000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1042368023000244"],"URL":"https:\/\/doi.org\/10.1016\/j.nec.2023.02.012","relation":{},"ISSN":["1042-3680"],"issn-type":[{"value":"1042-3680","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Systemic Approaches for the Management of Meningiomas","name":"articletitle","label":"Article Title"},{"value":"Neurosurgery Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nec.2023.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}